Impfen bei Immundefizienz

Anwendungshinweise zu den von der Ständigen Impfkommission empfohlenen Impfungen(I) Grundlagenpapier
  • Tim Niehues
  • Christian Bogdan
  • Jane Hecht
  • Thomas Mertens
  • Miriam Wiese-Posselt
  • Fred Zepp
Bekanntmachungen – Amtliche Mitteilungen


  1. 1.
    Mitteilung der Ständigen Impfkommission (STIKO) am Robert Koch-Institut: Hinweise zu Impfungen für Patienten mit Immundefizienz, Sonderdruck (2005).Google Scholar
  2. 2.
    Valour F, Cotte L, Voirin N, Godinot M, Ader F, Ferry T et al (2014) Vaccination coverage against hepatitis A and B viruses, Streptococcus pneumoniae, seasonal flu, and A(H1N1)2009 pandemic influenza in HIV-infected patients. Vaccine 32(35:4558–4564CrossRefGoogle Scholar
  3. 3.
    Grabmeier-Pfistershammer K, Herkner H, Touzeau-Roemer V, Rieger A, Burgmann H, Poeppl W (2015) Low tetanus, diphtheria and acellular pertussis (Tdap) vaccination coverage among HIV infected individuals in Austria. Vaccine 33(32):3929–3932CrossRefPubMedGoogle Scholar
  4. 4.
    Loubet P, Kerneis S, Groh M, Loulergue P, Blanche P, Verger P et al (2015) Attitude, knowledge and factors associated with influenza and pneumococcal vaccine uptake in a large cohort of patients with secondary immune deficiency. Vaccine 33(31):3703–3708CrossRefPubMedGoogle Scholar
  5. 5.
    Durham MD, Buchacz K, Armon C, Patel P, Wood K, Brooks JT (2011) Rates and correlates of influenza vaccination among HIV-infected adults in the HIV Outpatient Study (HOPS), USA, 1999-2008. Prev Med 53(1-2:89–94CrossRefGoogle Scholar
  6. 6.
    Orange JS, Ballow M, Stiehm ER, Ballas ZK, Chinen J, De La Morena M et al (2012) Use and interpretation of diagnostic vaccination in primary immunodeficiency: a working group report of the Basic and Clinical Immunology Interest Section of the American Academy of Allergy, Asthma & Immunology. J Allergy Clin Immunol 130:S1–S24CrossRefPubMedGoogle Scholar
  7. 7.
    Rubin LG, Levin MJ, Ljungman P, Davies EG, Avery R, Tomblyn M et al (2014) 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis 58(3:309–318CrossRefGoogle Scholar
  8. 8.
    Committee to Review Adverse Effects of V, Institute of M. In: Stratton K, Ford A, Rusch E, Clayton EW, editors. Adverse Effects of Vaccines: Evidence and Causality. Washington (DC): National Academies Press (US) Copyright 2012 by the National Academy of Sciences. All rights reserved.; 2011.Google Scholar
  9. 9.
    Fine PEM (1993) Herd immunity: history, theory, practice. Epidemiol Rev 15:265–302CrossRefPubMedGoogle Scholar
  10. 10.
    Anderson RM, May RM (1991) Infectious Diseases of Humans: Dynamics and Control. University Press, OxfordGoogle Scholar
  11. 11.
    Ständigen Impfkommission (STIKO) am Robert Koch-Institut (2016) 2017. Epidemiol Bull 2016:34Google Scholar
  12. 12.
    Shearer WT, Fleisher TA, Buckley RH, Ballas Z, Ballow M, Blaese RM et al (2014) Recommendations for live viral and bacterial vaccines in immunodeficient patients and their close contacts. J Allergy Clin Immunol 133(4):961–966CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Esposito S, Prada E, Lelii M, Castellazzi L (2015) Immunization of children with secondary immunodeficiency. Hum Vaccin Immunother 11(11):2564–2570CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Principi N, Esposito S (2014) Vaccine use in primary immunodeficiency disorders. Vaccine 32(30):3725–3731CrossRefPubMedGoogle Scholar
  15. 15.
    Aguilar C, Malphettes M, Donadieu J, Chandesris O, Coignard-Biehler H, Catherinot E et al (2014) Prevention of infections during primary immunodeficiency. Clin Infect Dis 59(10):1462–1470CrossRefPubMedGoogle Scholar
  16. 16.
    Farmand S, Baumann U, von Bernuth H, Borte M, Foerster-Waldl E, Franke K et al (2011) Interdisciplinary AWMF guideline for the diagnostics of primary immunodeficiency. Klin Padiatr 223(6):378–385CrossRefPubMedGoogle Scholar
  17. 17.
    Netea MG, Joosten LA, Latz E, Mills KH, Natoli G, Stunnenberg HG et al (2016) Trained immunity: A program of innate immune memory in health and disease. Science 352(6284):aaf1098CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Warfel JM, Edwards KM (2015) Pertussis vaccines and the challenge of inducing durable immunity. Curr Opin Immunol 35:48–54CrossRefPubMedGoogle Scholar
  19. 19.
    Pollard AJ, Perrett KP, Beverley PC (2009) Maintaining protection against invasive bacteria with protein-polysaccharide conjugate vaccines. Nat Rev Immunol 9(3):213–220CrossRefPubMedGoogle Scholar
  20. 20.
    Mitchell R, Kelly DF, Pollard AJ, Truck J (2014) Polysaccharide-specific B cell responses to vaccination in humans. Hum Vaccin Immunother 10(6):1661–1668CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    McKelvie B, Top K, McCusker C, Letenyi D, Issekutz TB, Issekutz AC (2014) Fatal pneumococcal meningitis in a 7-year-old girl with interleukin-1 receptor activated kinase deficiency (IRAK-4) despite prophylactic antibiotic and IgG responses to Streptococcus pneumoniae vaccines. J Clin Immunol 34(3):267–271CrossRefPubMedGoogle Scholar
  22. 22.
    Poolman J, Borrow R (2011) Hyporesponsiveness and its clinical implications after vaccination with polysaccharide or glycoconjugate vaccines. Expert Rev Vaccines 10(3):307–322CrossRefPubMedGoogle Scholar
  23. 23.
    Remschmidt CHT, Wichmann O, Bogdan C, Falkenhorst G (2017) Effectiveness, immunogenicity and safety of revaccinations with the 23-valent pneumococcal polysaccharide vaccine in the elderly: a systematic review. Bmc Infect Dis 16(1):711CrossRefGoogle Scholar
  24. 24.
    Falkenhorst GRC, Harder T, Wichmann O, Glodny S, Hummers-Pardier E, von Kries R, Weinke T, Ledig T, Bogdan C (2017) Background paper to the updated pneumococcal vaccination recommendation for older adults in Germany. Bundesgesundheitsblatt 59(12):1623–1657CrossRefGoogle Scholar
  25. 25.
    Kobrynski L (2015) Newborn screening for severe combined immune deficiency (technical and political aspects). Curr Opin Allergy Clin Immunol 15(6):539–546CrossRefPubMedGoogle Scholar
  26. 26.
    Buelow BJ, Verbsky JW, Routes JM (2016) Newborn screening for SCID: lessons learned. Expert Rev Hematol 9(6):579–584CrossRefPubMedGoogle Scholar
  27. 27.
    Siegrist CA, Aspinall R (2009) B-cell responses to vaccination at the extremes of age. Nat Rev Immunol 9(3):185–194CrossRefPubMedGoogle Scholar
  28. 28.
    Newport MJ, Goetghebuer T, Weiss HA, Whittle H, Siegrist CA, Marchant A et al (2004) Genetic regulation of immune responses to vaccines in early life. Genes Immun 5(2):122–129CrossRefPubMedGoogle Scholar
  29. 29.
    Whaley MJ, Rose C, Martinez J, Laher G, Sammons DL, Smith JP et al (2010) Interlaboratory comparison of three multiplexed bead-based immunoassays for measuring serum antibodies to pneumococcal polysaccharides. Clin Vaccine Immunol 17(5):862–869CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Björkholm B, Bottiger M, Christenson B, Hagberg L (1986) Antitoxin antibody levels and the outcome of illness during an outbreak of diphtheria among alcoholics. Scand J Infect Dis 18(3):235-239CrossRefPubMedGoogle Scholar
  31. 31.
    Bigl S, Drechsler R (1997) Bestimmung von Diphterieantitoxin im Serum - ein Methodenvergleich. Mikrobiologie :93–95Google Scholar
  32. 32.
    Lumio JT et al (2003) What is a protective level of diphtheria antitoxin antibodies? Abstract 43rd Intersci Conf Antimicr Agents ChemotherGoogle Scholar
  33. 33.
    Fiore AE, Finestone SM, Bell BP (2008) Vaccine, Elsevier, Philadelphia, S 177–203Google Scholar
  34. 34.
    Jack AD, Hall AJ, Maine N, Mendy M, Whittle HC (1999) What level of hepatitis B antibody is protective? J Infect Dis 179(2):489–492CrossRefPubMedGoogle Scholar
  35. 35.
    Kayhty H (1994) Difficulties in establishing a serological correlate of protection after immunization with Haemophilus influenzae conjugate vaccines. Biologicals 22(4):397–402CrossRefPubMedGoogle Scholar
  36. 36.
    Zepp F, Schmitt HJ, Cleerbout J, Verstraeten T, Schuerman L, Jacquet JM (2009) Review of 8 years of experience with Infanrix hexa (DTPa-HBV-IPV/Hib hexavalent vaccine). Expert Rev Vaccines 8(6):663–678CrossRefPubMedGoogle Scholar
  37. 37.
    Chen RT, Markowitz LE, Albrecht P, Stewart JA, Mofenson LM, Preblud SR et al (1990) Measles antibody: reevaluation of protective titers. J Infect Dis 162(5):1036–1042CrossRefPubMedGoogle Scholar
  38. 38.
    Weibel RE, Buynak EB, McLean AA, Hilleman MR (1995) Long-term follow-up for immunity after monovalent or combined live measles, mumps, and rubella virus vaccines. Pediatrics 56:380–387Google Scholar
  39. 39.
  40. 40.
    MacNeil J, al. e (2015) Use of Serogroup B Meningococcal Vaccines in Adolescents and Young Adults: Recommendations of the Advisory Committee on Immunization Practices, 2015. Morb Mortal Wkly Rep 64(41):1171–1176CrossRefGoogle Scholar
  41. 41.
    Jodar L, Butler J, Carlone G, Dagan R, Goldblatt D, Kayhty H et al (2003) Serological criteria for evaluation and licensure of new pneumococcal conjugate vaccine formulations for use in infants. Vaccine 21(23):3265–3272CrossRefPubMedGoogle Scholar
  42. 42.
    Siber GR, Chang I, Baker S, Fernsten P, O'Brien KL, Santosham M et al (2007) Estimating the protective concentration of anti-pneumococcal capsular polysaccharide antibodies. Vaccine 25(19):3816–3826CrossRefPubMedGoogle Scholar
  43. 43.
    Faden H, Modlin JF, Thoms ML, McBean AM, Ferdon MB, Ogra PL (1990) Comparative evaluation of immunization with live attenuated and enhanced-potency inactivated trivalent poliovirus vaccines in childhood: systemic and local immune responses. J Infect Dis 162(6):1291–1297CrossRefPubMedGoogle Scholar
  44. 44.
    Matter L, Kogelschatz K, Germann D (1997) Serum levels of rubella virus antibodies indicating immunity: response to vaccination of subjects with low or undetectable antibody concentrations. J Infect Dis 175(4):749–755CrossRefPubMedGoogle Scholar
  45. 45.
    Sauerbrei A, Schafler A, Hofmann J, Schacke M, Gruhn B, Wutzler P (2012) Evaluation of three commercial varicella-zoster virus IgG enzyme-linked immunosorbent assays in comparison to the fluorescent-antibody-to-membrane-antigen test. Clin Vaccine Immunol 19(8):1261–1268CrossRefPubMedPubMedCentralGoogle Scholar
  46. 46.
    Sauerbrei A, Farber I, Brandstadt A, Schacke M, Wutzler P (2004) Immunofluorescence test for sensitive detection of varicella-zoster virus-specific IgG: an alternative to fluorescent antibody to membrane antigen test. J Virol Methods 119(1):25–30CrossRefPubMedGoogle Scholar
  47. 47.
    Sauerbrei A, Prager J, Hengst U, Zintl F, Wutzler P (1997) Varicella vaccination in children after bone marrow transplantation. Bone Marrow Transplant 20(5):381–383CrossRefPubMedGoogle Scholar
  48. 48.
    Plotkin SA (2010) Correlates of protection induced by vaccination. Clin Vaccine Immunol 17(7):1055–1065CrossRefPubMedPubMedCentralGoogle Scholar
  49. 49.
    Morillo-Gutierrez B, Worth A, Valappil M, Gaspar HB, Gennery AR (2015) Chronic Infection with Rotavirus Vaccine Strains in UK Children with Severe Combined Immunodeficiency. Pediatr Infect Dis J 34(9):1040–1041CrossRefPubMedGoogle Scholar
  50. 50.
    Perelygina L, Plotkin S, Russo P, Hautala T, Bonilla F, Ochs HD et al (2016) Rubella persistence in epidermal keratinocytes and granuloma M2 macrophages in patients with primary immunodeficiencies. J Allergy Clin Immunol 138(5):1436–1439.e1CrossRefPubMedPubMedCentralGoogle Scholar
  51. 51.
    Neven B, Perot P, Bruneau J, Pasquet M, Ramirez M, Diana JS et al (2017) Cutaneous and Visceral Chronic Granulomatous Disease Triggered by a Rubella Virus Vaccine Strain in Children With Primary Immunodeficiencies. Clin Infect Dis 64(1):83–86CrossRefPubMedGoogle Scholar
  52. 52.
    Bitnun A, Shannon P, Durward A, Rota PA, Bellini WJ, Graham C et al (1999) Measles inclusion-body encephalitis caused by the vaccine strain of measles virus. Clin Infect Dis 29(4):855–861CrossRefPubMedGoogle Scholar
  53. 53.
    Iroh TP (2014) Measles vaccine strain from the skin rash of a DiGeorge patient receiving tumor necrosis factor inhibitor. Pediatr Infect Dis J 33(1):117CrossRefGoogle Scholar
  54. 54.
    CDC (1996) Measles pneumonitis following measles-mumps-rubella vaccination of a patient with HIV infection, 1993. MMWR Morb Mortal Wkly Rep 45(28):603–606Google Scholar
  55. 55.
    Leung J, Siegel S, Jones JF, Schulte C, Blog D, Schmid DS et al (2014) Fatal varicella due to the vaccine-strain varicella-zoster virus. Hum Vaccin Immunother 10(1):146–149CrossRefPubMedGoogle Scholar
  56. 56.
    Bayer DK, Martinez CA, Sorte HS, Forbes LR, Demmler-Harrison GJ, Hanson IC et al (2014) Vaccine-associated varicella and rubella infections in severe combined immunodeficiency with isolated CD4 lymphocytopenia and mutations in IL7R detected by tandem whole exome sequencing and chromosomal microarray. Clin Exp Immunol 178(3):459–469CrossRefPubMedPubMedCentralGoogle Scholar
  57. 57.
    Dutmer CM, Asturias EJ, Smith C, Dishop MK, Schmid DS, Bellini WJ et al (2015) Late Onset Hypomorphic RAG2 Deficiency Presentation with Fatal Vaccine-Strain VZV Infection. J Clin Immunol 35(8):754–760CrossRefPubMedPubMedCentralGoogle Scholar
  58. 58.
    Sabry A, Hauk PJ, Jing H, Su HC, Stence NV, Mirsky DM et al (2014) Vaccine strain varicella-zoster virus-induced central nervous system vasculopathy as the presenting feature of DOCK8 deficiency. J Allergy Clin Immunol 133(4):1225–1227CrossRefPubMedPubMedCentralGoogle Scholar
  59. 59.
    Banovic T, Yanilla M, Simmons R, Robertson I, Schroder WA, Raffelt NC et al (2011) Disseminated varicella infection caused by varicella vaccine strain in a child with low invariant natural killer T cells and diminished CD1d expression. J Infect Dis 204(12):1893–1901CrossRefPubMedGoogle Scholar
  60. 60.
    Waters V, Peterson KS, LaRussa P (2007) Live viral vaccines in a DiGeorge syndrome patient. Arch Dis Child 92(6):519–520CrossRefPubMedGoogle Scholar
  61. 61.
    Schrauder A, Henke-Gendo C, Seidemann K, Sasse M, Cario G, Moericke A et al (2007) Varicella vaccination in a child with acute lymphoblastic leukaemia. Lancet 369(9568):1232CrossRefPubMedGoogle Scholar
  62. 62.
    Costa E, Buxton J, Brown J, Templeton KE, Breuer J, Johannessen I (2016) Fatal disseminated varicella zoster infection following zoster vaccination in an immunocompromised patient. BMJ Case Rep. doi: 10.1136/bcr-2015-212688Google Scholar
  63. 63.
    Bhalla P, Forrest GN, Gershon M, Zhou Y, Chen J, LaRussa P et al (2015) Disseminated, persistent, and fatal infection due to the vaccine strain of varicella-zoster virus in an adult following stem cell transplantation. Clin Infect Dis 60(7):1068–1074PubMedGoogle Scholar
  64. 64.
    Guo J, Bolivar-Wagers S, Srinivas N, Holubar M, Maldonado Y (2015) Immunodeficiency-related vaccine-derived poliovirus (iVDPV) cases: a systematic review and implications for polio eradication. Vaccine 33(10):1235–1242CrossRefPubMedGoogle Scholar
  65. 65.
    de Silva R, Gunasena S, Ratnayake D, Wickremesinghe GD, Kumarasiri CD, Pushpakumara BA et al (2012) Prevalence of prolonged and chronic poliovirus excretion among persons with primary immune deficiency disorders in Sri Lanka. Vaccine 30(52):7561–7565CrossRefPubMedGoogle Scholar
  66. 66.
    Shaghaghi M, Parvaneh N, Ostad-Rahimi P, Fathi SM, Shahmahmoodi S, Abolhassani H et al (2014) Combined immunodeficiency presenting with vaccine-associated paralytic poliomyelitis: a case report and narrative review of literature. Immunol Invest 43(3):292–298CrossRefPubMedGoogle Scholar
  67. 67.
    Trimble R, Atkins J, Quigg TC, Burns CC, Wallace GS, Thomas M et al (2014) Vaccine-associated paralytic poliomyelitis and BCG-osis in an immigrant child with severe combined immunodeficiency syndrome - Texas, 2013. MMWR Morb Mortal Wkly Rep 63(33:721–724Google Scholar
  68. 68.
    Canessa C, Romano F, Lippi F, Bianchi L, Kashef S, Rezaei N et al (2013) Bcgitis and vaccine-derived poliovirus infection in a patient with a novel deletion in RAG1 binding site. Int J Immunopathol Pharmacol 26(2):511–515CrossRefPubMedGoogle Scholar
  69. 69.
    Seligman SJ (2014) Risk groups for yellow fever vaccine-associated viscerotropic disease (YEL-AVD). Vaccine 32(44):5769–5775CrossRefPubMedGoogle Scholar
  70. 70.
    Thomas RE, Lorenzetti DL, Spragins W, Jackson D, Williamson T (2012) The safety of yellow fever vaccine 17D or 17DD in children, pregnant women, HIV+ individuals, and older persons: systematic review. Am J Trop Med Hyg 86(2):359–372CrossRefPubMedPubMedCentralGoogle Scholar
  71. 71.
    Monath TP (2012) Review of the risks and benefits of yellow fever vaccination including some new analyses. Expert Rev Vaccines 11(4):427–448CrossRefPubMedGoogle Scholar
  72. 72.
    Traiber C (2011) Infant meningoencephalitis caused by yellow fever vaccine virus transmitted via breastmilk. J Pediatr (Rio J) 87(3):269–272Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2017

Authors and Affiliations

  • Tim Niehues
    • 1
  • Christian Bogdan
    • 2
    • 3
  • Jane Hecht
    • 4
  • Thomas Mertens
    • 3
    • 5
  • Miriam Wiese-Posselt
    • 4
  • Fred Zepp
    • 3
    • 6
  1. 1.Zentrum für Kinder- und JugendmedizinHelios Klinikum KrefeldKrefeldDeutschland
  2. 2.Institut für klinische Mikrobiologie, Immunologie und Hygiene,Universitätsklinikum ErlangenErlangenDeutschland
  3. 3.3Ständige Impfkommission (STIKO)Robert Koch-InstitutBerlinDeutschland
  4. 4.Abteilung für Infektionsepidemiologie, Fachgebiet ImpfpräventionRobert Koch-InstitutBerlinDeutschland
  5. 5.Institut für VirologieUniversitätsklinikum UlmUlmDeutschland
  6. 6.Zentrums für Kinder- und JugendmedizinUniversitätsmedizin MainzMainzDeutschland

Personalised recommendations